共 50 条
- [41] Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective StudyLIVER CANCER, 2021, 10 (02) : 107 - 114Yoo, ChanghoonKim, Jwa HoonRyu, Min-HeePark, Sook RyunLee, DanbiKim, Kang MoShim, Ju HyunLim, Young-SukLee, Han ChuLee, JoycelynTai, DavidChan, Stephen LamRyoo, Baek-Yeol
- [42] Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countriesANNALS OF ONCOLOGY, 2023, 34 : S603 - S603Lee, C-K.Yoo, C.Park, S. J.Kim, H.Korphaisarn, K.Kim, J. W.Chen, S-C.Kim, I.Kim, M.Chan, S. L.Kim, J. W.Tai, D. W. M.Oh, S. B.Chen, C-T.Bae, W. K.Kim, H.Hong, J. Y.Choi, H. J.Chon, H. J.Lee, M. A.
- [43] Safety and efficacy preliminary analysis of first-line systemic therapy with atezolizumab plus bevacizumab in Spanish patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: phase IIIb ATHECA trialJOURNAL OF HEPATOLOGY, 2024, 80 : S455 - S456Reig, MariaLuque, NataliaLledo, Jose LuisMatilla, AnaMontero, Jose LuisPazo-Cid, RobertoVarela, MariaBorras, MarOrdonez, Jose-ManuelArgemi, Josep MariaBruix, JordiGomez-Martin, CarlosPerez-Lopez, RaquelRimola, JordiSangro, BrunoSastre, Javier
- [44] Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysisEUROPEAN JOURNAL OF CANCER, 2018, 105 : 1 - 9McNamara, Mairead GeraldineSlagter, Astrid E.Nuttall, ChristinaFrizziero, MelissaPihlak, RilleLamarca, AngelaTariq, NoorValle, Juan W.Hubner, Richard A.Knox, Jennifer J.Amir, Eitan
- [45] Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A plus B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Alkadimi, MunafFierro, Maria ElenaBoyle, Lauren DiazLucero, KanaFranklin, KathleenMader, MichaelNooruddin, Zohra
- [46] Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-AnalysisCANCERS, 2024, 16 (16)Peng, Tzu-RongWeng, Yi-FangWu, Ta-WeiWu, Chao-ChuanChou, Yi-ChunHsu, Ching-Sheng
- [48] Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Yoo, ChanghoonKim, Jwa HoonRyu, Min-HeePark, Sook RyunLee, Joycelyn Jie XinTai, Wai Meng DavidChan, Stephen LamRyoo Baek-Yeol
- [49] KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosisJOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS647 - TPS647Singal, AmitSpencer, Kristen ReneeKulik, LauraVillanueva, AugustoIyer, RenukaChakalakal, ShilpaKothari, RuchaKo, JinnieReilly, NorelleStark, ThomasEl-Khoueiry, Anthony B.
- [50] Efficacy and safety of sorafenib as first-line therapy of patients (pts) with advanced Child-Pugh B Hepatocellular Carcinoma (HCC): A systematic review and meta-analysisEUROPEAN JOURNAL OF CANCER, 2015, 51 : S446 - S446McNamara, M.Slagter, A.Rigby, C.Lamarca, A.Valle, J.Hubner, R.Amir, E.